$PBIO company leads in development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of an innovative workflow for the analysis of proteins from cancer biopsy samples.


Dr. Larry Maxwell, MD, gynecologic oncologist and Chair of OB-GYN at Inova Fairfax Hospital, “the conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the “seed”) and also the micro-environment (the “soil”) in which it grows. Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies. Technology provided by Pressure BioSciences has become an essential requirement for our novel workflow in meeting our goals.”